RemeGen Co. Ltd. Class A
688331
Rangering i aksjer
#2475
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Aksjekurs
$14.13
Markedsverdi
$7.91B
Endring (1 dag)
-2.50%
Endring (1 år)
3.41%
Land
CN
Handel RemeGen Co. Ltd. Class A (688331)
Kategori
Healthcare
EPS for RemeGen Co. Ltd. Class A (688331)
EPS per June 2026 TTM: $1.51
Ifølge de siste økonomiske rapportene og aksjekursen til RemeGen Co. Ltd. Class A er selskapets nåværende EPS (TTM) $1.51. Ved slutten av 2023 hadde selskapet en EPS på $-0.40, en økning sammenlignet med EPS-en i 2022 som var $-0.27.
EPS-historikk for RemeGen Co. Ltd. Class A fra 2018 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $1.51 | -506.95% |
| 2024 | $-0.37 | -5.46% |
| 2023 | $-0.40 | 45.17% |
| 2022 | $-0.27 | -403.79% |
| 2021 | $0.09 | -134.26% |
| 2020 | $-0.26 | 102.63% |
| 2019 | $-0.13 | 58.72% |
| 2018 | $-0.08 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | 1,050.30% |
US
|
|
| $-7.98 | -629.99% |
US
|
|
| $-5.29 | -451.33% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 1,742.33% |
NL
|
